Research
Hormonal
Tirzepatide (10-15 mg) produces greater mean weight loss than semaglutide (2.4 mg) in head-to-head comparisons, achieving reductions of up to 20.9%.
Tirzepatide is a weekly injection that targets two hormones (GIP and GLP-1) to maximize weight loss, often resulting in ~20% body weight reduction. It requires slow dose escalation to manage stomach side effects.
StrongSupportsHIGH confidence
SURMOUNT-1 observed mean reductions in baseline body weight of 19.5% and 20.9% with tirzepatide doses of 10 and 15 mg/d, respectively, compared with a 3.1% for placebo.
Why this rating
Based on Phase 3 SURMOUNT-1 trial results.
Source
Evolving Approaches for Pharmacological Therapy of Obesity
Ariana M. Chao et al. · The Annual Review of Pharmacology and Toxicology · 2024
DOI 10.1146/annurev-pharmtox-031124-101146
narrative_reviewCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic pharmacotherapy with GLP-1 receptor agonists (semaglutide 2.4 mg) and dual agonists (tirzepatide 10-15 mg) produces significantly greater and more sustained weight loss than behavioral interventions alone by neutralizing counter-regulatory physiological mechanisms.Strong
- Discontinuation of GLP-1 based therapies leads to significant weight regain, indicating that obesity requires chronic management rather than short-term treatment.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →